Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “underweight” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Tuesday, August 8th. They presently have a $69.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $60.00. Cantor Fitzgerald’s price target points to a potential downside of 33.70% from the company’s current price.
The analysts wrote, “In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients’ increase of +1% at 24 weeks,” the firm said.”Additionally, CONTROL demonstrated atorvastatin’s ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL.”
A number of other equities analysts have also commented on the stock. Oppenheimer Holdings, Inc. reissued an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, April 12th. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a report on Monday, July 10th. They issued a “buy” rating and a $275.00 price target on the stock. Credit Suisse Group increased their price target on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a report on Friday, May 5th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target on the stock in a report on Tuesday, July 11th. Finally, Laidlaw raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price target on the stock in a report on Friday, May 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $203.67.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.11% on Tuesday, reaching $104.08. 302,612 shares of the company were exchanged. The stock’s market capitalization is $2.61 billion. The firm has a 50 day moving average price of $117.73 and a 200-day moving average price of $117.69. Intercept Pharmaceuticals has a 12-month low of $96.63 and a 12-month high of $172.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s revenue was up 459.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.14) EPS. On average, analysts predict that Intercept Pharmaceuticals will post ($14.05) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/08/19/intercept-pharmaceuticals-inc-icpt-given-underweight-rating-at-cantor-fitzgerald-updated.html.
In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the sale, the director now owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark Pruzanski sold 40,000 shares of the stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the sale, the chief executive officer now directly owns 611,718 shares of the company’s stock, valued at approximately $80,012,714.40. The disclosure for this sale can be found here. Insiders have sold a total of 47,462 shares of company stock valued at $6,130,938 in the last three months. 9.20% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Intercept Pharmaceuticals by 0.7% in the second quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock valued at $454,094,000 after buying an additional 25,958 shares in the last quarter. Carmignac Gestion boosted its stake in Intercept Pharmaceuticals by 0.4% in the second quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock valued at $246,449,000 after buying an additional 7,400 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after buying an additional 57,149 shares during the last quarter. State Street Corp raised its position in shares of Intercept Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after buying an additional 54,523 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Intercept Pharmaceuticals by 17.0% in the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after buying an additional 41,856 shares during the last quarter. 83.05% of the stock is owned by hedge funds and other institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.